NCT04145297 - Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 17, 2020

Primary Completion Date

June 10, 2022

Study Completion Date

August 18, 2022

Conditions

Gastrointestinal Neoplasms

Interventions

DRUG

Ulixertinib

"Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles"

DRUG

Hydroxychloroquine

Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City